Reactions Weekly

, Volume 1697, Issue 1, pp 1–1 | Cite as

Saudi FDA requests labelling update for ofatumumab

News item
  • 15 Downloads

Reference

  1. Saudi Food and Drug Authority (SFDA). Risk of Progressive Multifocal Encephalopathy (PML) Following Ofatumumab Use. Internet Document : 26 Mar 2018. Available from: URL: https://www.sfda.gov.sa/en/drug/about/sector_departments/national_pharmacovigilance_center/Documents/Ofatumumab-PML.pdf

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations